KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) EBITDA (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed EBITDA for 17 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 123.18% to $1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.8 billion, a 134.41% increase, with the full-year FY2025 number at $6.8 billion, up 178.32% from a year prior.
  • EBITDA was $1.1 billion for Q4 2025 at Bristol Myers Squibb, down from $2.2 billion in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $2.5 billion in Q4 2021 to a low of -$11.8 billion in Q1 2024.
  • A 5-year average of -$41.8 million and a median of $1.2 billion in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: surged 769.39% in 2021, then tumbled 640.92% in 2024.
  • Bristol Myers Squibb's EBITDA stood at $2.5 billion in 2021, then plummeted by 37.42% to $1.6 billion in 2022, then plummeted by 167.7% to -$1.1 billion in 2023, then plummeted by 332.96% to -$4.6 billion in 2024, then skyrocketed by 123.18% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's EBITDA are $1.1 billion (Q4 2025), $2.2 billion (Q3 2025), and $1.2 billion (Q2 2025).